Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607502 | 1.00 | TP53 (0.45) | TP53SLC7A5ALDH1A1TSHRMAPT | |
| SCHEMBL13542998 | 0.82 | TP53 (0.42) | TP53SLC7A5ALDH1A1TSHRMAPT | |
| SCHEMBL5514917 | 0.82 | TP53 (0.42) | TP53SLC7A5ALDH1A1TSHRMAPT | |
| SCHEMBL1604917 | 0.82 | ALDH1A1 (0.39) | TP53SLC7A5ALDH1A1TSHRMAPT | |
| SCHEMBL10486549 | 0.81 | TP53 (0.43) | TP53SLC7A5ALDH1A1TSHRMAPT | |
| SCHEMBL25004681 | 0.78 | TSHR (0.47) | TP53SLC7A5ALDH1A1TSHRMAPT | |
| SCHEMBL17777229 | 0.78 | TP53 (0.38) | TP53SLC7A5ALDH1A1TSHRMAPT | |
| Cadaverine Tartrate SCHEMBL30041704 | 0.78 | TSHR (0.56) | TP53SLC7A5ALDH1A1TSHRMAPT | |
| SCHEMBL22355731 | 0.78 | TP53 (0.38) | TP53SLC7A5ALDH1A1TSHRMAPT | |
| SCHEMBL17915472 | 0.78 | TP53 (0.32) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | disclosed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | disclosed |
| US-6384228-B2 | EPIBATIDINE; ANALGESICS; ANIMAL EXTRACTS | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| US-20020010339-A1 | METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010339-A1 | METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF | DHPS, ALAD, HAAO | TP53 4588/4885SLC7A5 4190/4885ALDH1A1 242/4885 |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | TP53 4311/4885SLC7A5 4466/4885ALDH1A1 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.